MicroDAO
MicroDAO, Varun KothamachuDecentralising the Fight Against AMR by Funding the next generation of AMR Solutions (Antimicrobials, Diagnostics, and Vaccines)
| Platform |  | Pricing | Only free issues | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 23 | Subscribers | Read | microdao.substack.com |
Curious about how many subscribers MicroDAO has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Act Now: Protect Our Present, Secure Our Future
Every year since 2015, World AMR Awareness Week (WAAW) has brought together global voices united by one mission: to confront the growing threat of antimicrobial resistance (AMR).
Building, Refining, and Staying True to Our Vision
As we close another quarter, we wanted to share what has been happening behind the scenes at MicroDAO, the progress, the challenges, and the quiet work shaping our next phase.
Learning from the Pioneers: What Other BioDAOs Teach Us About Building Sustainable Science
In our previous post, we explored why AMR Innovation needs new funding models rather than the traditional models of funding, and how Web3 can help unlock new ways to sustain antimicrobial resistance (AMR) innovation. If you missed it, you c...
Why AMR Innovation Needs New Funding Models, and How Web3 Can Help
In our earlier posts, we introduced MicroDAO’s vision: to build a new, decentralised infrastructure for tackling antimicrobial resistance (AMR), one of the most urgent and complex global health challenges of our time. We shared how AMR inno...
Authors
The writers behind this newsletter.
\ud83d\ude80 Decentralizing the Fight Against AMR | \ud83c\udf0d Community-driven funding for antimicrobials, vaccines & diagnostics | \ud83c\udfdb Powered by transparent governance
Senior Product & Solutions Manager@lifebit. past: Product@digi_bio, postdoc@EdinburghUniversity and @BabrahamInstitute. started @CafeSynthetiqueEdinburgh
Frequently Asked Questions
How can I access the email archive for MicroDAO?
You can find recent issues that have been published by MicroDAO on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does MicroDAO have?
To see how many people subscribe to MicroDAO, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in MicroDAO?
Newsletter advertising can be extremely effective when it's done right. Before you pitch MicroDAO as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like MicroDAO?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact MicroDAO using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to MicroDAO?
Scroll up to where it says Similar Newsletters to see other publications like MicroDAO. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact MicroDAO?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.